



William C. Rives, CFA
 Portfolio Manager
 (industry since 2013)

Objective

Putnam BioRevolution ETF seeks long term capital appreciation.

Type

Active, fully transparent, traditional ETF with daily disclosure of portfolio holdings to public investors and traders

Ticker	CUSIP
SYNB	746729805

Primary exchange

NYSE

Fund distributor

Foreside Fund Services, LLC

Inception

September 29, 2022

Benchmark

S&P 500 Index

Number of holdings

40

Total expense ratio

0.70%

Putnam BioRevolution™ ETF (SYNB)

Investing in companies that are leveraging innovation within biology

Pursues transformative growth across sectors

The economic impact of the biology revolution is spreading beyond health care, with potential to transform multiple sectors and drive investment opportunities.

Collaborative research process

A benchmark-agnostic approach leverages unique, integrated insights of Putnam sector analysts and the Sustainable Equity team.

Concentrated portfolio

The manager seeks outperformance by investing in 30-50 high-conviction stocks selected through disciplined portfolio construction and risk management.


Top 10 holdings

	Portfolio	Benchmark	Over/Under
Thermo Fisher Scientific	8.0%	0.5%	7.5%
Danaher	6.6	0.4	6.2
Alphabet	5.4	3.8	1.6
NVIDIA	4.8	3.1	1.7
Bio-Rad Laboratories	4.8	0.0	4.8
Novozymes	4.5	0.0	4.5
Corteva	4.1	0.1	4.0
Lululemon	3.8	0.1	3.7
Ascendis Pharma	3.5	0.0	3.5
DowDuPont	3.5	0.1	3.4

Holdings represent 48.9% of the portfolio and will vary over time.

An active investment process

The ETF's investable universe is diversified primarily across the health care, materials, consumer staples, and consumer discretionary sectors, and represents more than 300 companies of all market cap sizes.



Health care	56.2%
Materials	20.8
Consumer staples	6.2
Communication services	5.4
Information technology	4.8
Consumer discretionary	3.8
Industrials	0.7

Cash and net other assets represent 2.0% of the portfolio.

Allocations will vary over time. Due to rounding, percentages may not equal 100%.

The unclassified sector, where applicable, includes exchange-traded funds and other securities not able to be classified by sector.

Annualized total return at net asset value

Inception: 9/29/22	NAV	Market price	Benchmark*
Q4	9.17%	9.02%	11.69%
1 year	12.25	12.13	26.29
Since inception	12.97	12.93	26.10

Current performance may be lower or higher than the quoted past performance, which cannot guarantee future results. Share price, principal value, and return will vary, and you may have a gain or loss when you sell your shares. Performance assumes reinvestment of distributions and does not account for taxes.

Shares of any ETF are bought and sold at market price (not NAV), may trade at a discount or premium to NAV, and are not individually redeemed from the fund. Brokerage commissions will reduce returns.

Returns less than one year are not annualized. For the most recent month-end performance, please call 1-833-228-5577 or visit the Fund's website at putnam.com.

A portfolio manager with unique experience seeing the impact of the biorevolution

William C. Rives, CFA, a Portfolio Manager and Analyst at Putnam, manages the ETF. Will is in a vital position for understanding the advance of the biology revolution: He researches companies in the medical technology, life sciences, and utility industries, using fundamental analysis and developing insights on their material sustainability issues. Will has served as a Portfolio Manager of Putnam Research Fund since 2019 and has worked in the investment industry since he joined Putnam in 2013.

*The S&P 500® Index is an unmanaged index of common stock performance. You cannot invest directly in an index.

Consider these risks before investing: Biology revolution companies face intense competition and potentially rapid product obsolescence. Biology revolution companies may be adversely affected by the loss or impairment of intellectual property rights and other proprietary information or changes in government regulations. The potential for an increased amount of required disclosure or lack of access to proprietary scientific information could negatively impact the performance of these companies.

Investments in small and/or midsize companies increase the risk of greater price fluctuations. Growth stocks may be more susceptible to earnings disappointments, and value stocks may fail to rebound. The value of investments in the fund's portfolio may fall or fail to rise over extended periods of time for a variety of reasons, including general economic, political, or financial market conditions; investor sentiment and market perceptions; government actions; geopolitical events or changes; and factors related to a specific issuer, geography, industry, or sector. These and other factors may lead to increased volatility and reduced liquidity in the fund's portfolio holdings.

As a non-diversified fund, the fund invests in fewer issuers and is more vulnerable than a more broadly diversified fund to fluctuations in the values of the securities it holds. Our investment techniques, analyses, and judgments may not produce the outcome we intend. The investments we select for the fund may not perform as well as other securities that we do not select for the fund. We, or the fund's other service providers, may experience disruptions or operating errors that could have a negative effect on the fund. You can lose money by investing in the fund.

You should consider the fund's investment objectives, risks, charges, and expenses carefully before you invest. This and other important information is contained in the fund's prospectus available on putnam.com or by calling 1-833-228-5577. Please read carefully before you invest.

Putnam ETFs are distributed by Foreside Fund Services, LLC. Putnam Retail Management, LP and Putnam Investments are Franklin Templeton companies and are not affiliated with Foreside Fund Services, LLC.

putnam.com